Overview of approaches to estimate real-world disease progression in lung cancer
AbstractBackground. Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Crit
AbstractBackground. Randomized clinical trials of novel treatments for solid tumors normally measure disease progression using the Response Evaluation Crit
The T-cell engager CX-904 had a favorable safety profile when administered as monotherapy in patients with advanced or metastatic solid tumors.
Abstract. Aspirin has been known for a long time and currently stays as a cornerstone of antithrombotic therapy in cardiovascular disease. In patients with
The FDA has granted a breakthrough device designation to Teal Wand, an at-home screening test for cervical cancer.
The 17th Annual Hematologic Malignancies Demystified returns in 2025. Access our virtual CME conference and earn CME/CE credits with our renowned faculty. Led by conference…
Maurie Markman, MD, expands on the debate regarding the appropriate primary outcome end point for improved clinical benefit in a trial.
Immunotherapy Advances aims to bring the latest news about immunotherapy trials to a diverse audience including researchers, health professionals, industry and
The Video Journal of Hematological Oncology (VJHemOnc) is a global, open-access video journal, dedicated to providing trusted and up-to-date medical information in order to improve…
AbstractBackground. A lack of consensus exists across guidelines as to which risk model should be used for the primary prevention of cardiovascular disease
This Viewpoint discusses use of anti–PD-1 monotherapy as the primary treatment option for patients with treatment-naive metastatic melanoma staining positive for PD-L1 over dual checkpoint…
Naval G. Daver, MD, highlights ongoing research efforts in relapsed/refractory AML, including combination regimens and pathways targeted by novel agents.